Effect of liraglutide 3.0 mg on eating behavior in patients with obesity

Effect of liraglutide 3.0 mg on eating behavior in patients with obesity

Introduction. One of the objectives of weight loss in obesity is to prevent metabolic disorders associated with it. An important component in the maintenance of the achieved results is a change of eating behavior.Goal: to study the effect of liraglutide 3.0 mg on the dynamics of metabolic parameters...

Full description

Bibliographic Details
Main Authors:	O. V. Logvinova, E. A. Troshina
Format:	Article
Language:	Russian
Published:	Remedium Group LLC 2021-05-01
Series:	Медицинский совет
Subjects:	glucagon-like peptide-1 agonist weight loss leptin dutch questionnaire lifestyle modification
Online Access:	https://www.med-sovet.pro/jour/article/view/6149

Similar Items

Prediction of early response to liraglutide therapy in patients with obesity
by: Oksana V. Logvinova, et al.
Published: (2020-06-01)

Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland
by: Christiane Lundegaard Haase, et al.
Published: (2021-08-01)

Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review
by: Xie Z, et al.
Published: (2022-12-01)

Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
by: Howell R, et al.
Published: (2019-04-01)

Short-term monotherapy with Liraglutide for weight management: A case study
by: Feras Almarshad
Published: (2019-01-01)

Energy intake as a short‐term biomarker for weight loss in adults with obesity receiving liraglutide: A randomized trial
by: Aditi R. Saxena, et al.
Published: (2021-06-01)

Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction?
by: Mahmoud M Mosli, et al.
Published: (2017-01-01)

Liraglutide; A New Hope for Obese Diabetics
by: Ajeet Kumar, et al.
Published: (2020-12-01)

A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg
by: Yutaka Seino, et al.
Published: (2022-08-01)

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update
by: Agnieszka Jakubowska, et al.
Published: (2024-02-01)

Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets
by: Thao D.V. Le, et al.
Published: (2023-06-01)

Efficacy of liraglutide 3 mig therapy in obesity and associated diseases
by: K. A. Komshilova, et al.
Published: (2018-03-01)

Effects of Treatment with Liraglutide Early after Surgical Intervention on Clinical Outcomes in Patients with Short Bowel Syndrome: A Pilot Observational “Real-Life” Study
by: Fabio Dario Merlo, et al.
Published: (2023-06-01)

EARLY EXPERIENCE OF GPP-1 LIRAGLUTIDE 3.0 MG ANALOGUE IN RUSSIA AND ITS EFFECT ON METABOLIC RISK FACTORS IN OBESITY PATIENTS
by: K. A. Komshilova, et al.
Published: (2017-12-01)

Gut microbiota mediates positive effects of liraglutide on dyslipidemia in mice fed a high-fat diet
by: Li Zhao, et al.
Published: (2022-12-01)

Brown Adipose Tissue: A New Potential Target for Glucagon-like Peptide 1 Receptor Agonists in the Treatment of Obesity
by: Tim Hropot, et al.
Published: (2023-05-01)

Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial
by: Linong Ji, et al.
Published: (2022-12-01)

Gglucagon-like peptide-1 analogue liraglutide (Saxenda®): mechanism of action, efficacy for the treatment of obesity
by: Tatiana I. Romantsova
Published: (2018-04-01)

Insulin–glucagon‐like peptide‐1 receptor agonist relay and glucagon‐like peptide‐1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open‐label trial study
by: Yumie Takeshita, et al.
Published: (2022-06-01)

Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity
by: David C. D. Hope, et al.
Published: (2021-09-01)

Promising areas of pharmacotherapy for obesity
by: M. A. Druzhilov, et al.
Published: (2021-04-01)

Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity
by: Ekaterina V. Tikhonenko, et al.
Published: (2018-12-01)

Association of glucagon‐like peptide‐1 receptor‐targeted imaging probe with in vivo glucagon‐like peptide‐1 receptor agonist glucose‐lowering effects
by: Takaaki Murakami, et al.
Published: (2020-11-01)

The Association of Peptide Hormones with Glycemia, Dyslipidemia, and Obesity in Lebanese Individuals
by: Murielle Abou-Samra, et al.
Published: (2022-11-01)

Liraglutide improved inflammation via mediating IL-23/Th-17 pathway in obese diabetic mice with psoriasiform skin
by: Pin Chen, et al.
Published: (2021-10-01)

Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial
by: Hongyu Cai, et al.
Published: (2023-01-01)

Is there an association between liraglutide use and female breast cancer in a real-world setting?
by: Funch D, et al.
Published: (2018-11-01)

Liraglutide Attenuates Aortic Valve Calcification in a High-Cholesterol-Diet-Induced Experimental Calcific Aortic Valve Disease Model in Apolipoprotein E-Deficient Mice
by: Yangzhao Zhou, et al.
Published: (2023-09-01)

GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review
by: Laurence Aoun, et al.
Published: (2024-03-01)

A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder
by: Kelly C. Allison, et al.
Published: (2023-04-01)

The Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients
by: Albaker W, et al.
Published: (2021-11-01)

Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides
by: L. Kořínková, et al.
Published: (2020-11-01)

An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism
by: Ren Q, et al.
Published: (2022-10-01)

GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report
by: Eva W. Iepsen, et al.
Published: (2020-04-01)

Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population
by: Funch D, et al.
Published: (2021-06-01)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
by: Marta Seghieri, et al.
Published: (2018-11-01)

Liraglutide protects against high-fat diet-induced kidney injury by ameliorating apoptosis
by: Riying Liang, et al.
Published: (2020-10-01)

Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE
by: Bo Liang, et al.
Published: (2020-07-01)

Novel Treatments for Obesity: Implications for Cancer Prevention and Treatment
by: Carla Micaela Cuttica, et al.
Published: (2023-08-01)

Experiences with Glucagon-Like Peptide-1 Receptor Agonist in Children with Acquired Hypothalamic Obesity
by: Jiska van Schaik, et al.
Published: (2020-08-01)